SCHEMBL20037697

SCHEMBL20037697

CC(C)(C)[Si](C)(C)OCC1CCN(Cc2ccc(N)nc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
DCPS Q96C86 2/20 0.39
SSTR5 P35346 1/20 0.38
ACHE P22303 4/20 0.38
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20037696 0.87 CD274 (0.39) ACHEKMT2A
SCHEMBL20037569 0.83 MCHR1 (0.39) SSTR5KMT2A
SCHEMBL31073195 0.82 PIK3CA (0.40)
SCHEMBL20037567 0.81 HRH3 (0.41) ACHEKMT2A
SCHEMBL20037566 0.79 MCHR1 (0.45) SSTR5KMT2A
SCHEMBL31072985 0.78 CCR5 (0.40) SSTR5KMT2A
SCHEMBL31073044 0.78 DRD2 (0.36)
SCHEMBL31073239 0.77 DRD4 (0.40)
SCHEMBL18291525 0.76 HRH3 (0.48) SSTR5ACHEKMT2A
SCHEMBL20037701 0.76 MCHR1 (0.36) SSTR5KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 US disclosed
EP-3305785-A1 PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Teijin Pharma Limited (JP) 2018-04-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF CDK4, CDK6, CDK16 DCPS 1503/4885SSTR5 2397/4885ACHE 4631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.